|  |  |  |  |
| --- | --- | --- | --- |
| **Table 1. Comparison between Saracatinib, Nintedanib, Pirfenidone** | | | |
| **Comparison aspect** | **Saracatinib** | **Ninetidanib** | **Pirfenidone** |
| Mechanism of action | Src kinase inhibitor. | Tyrosine kinase inhibitors. | TGF-𝛃 and fibronectin inhibitor as well as p38 MAPK in B lymphocytes. |
| TGF- 𝛃 expression of profibrotic genes. | Larger inhibitory effect including ACTA2, COL1A1, and SERPIN1 | Inhibits TGF- 𝛃 expression of profibrotic genes. | Inhibits TGF- 𝛃 expression of profibrotic genes. |
| TGF-β-induced Smad3 phosphorylation | Inhibitory effect. | No effect was found. | No effect was found. |
| Experimental pulmonary fibrosis reduction | Better effect. | Less effect. | Less effect. |
| Precision cuts lung slices results | Better effect in reducing pulmonary fibrosis. | Less effect. | Less effect. |

*TGF-𝛃; Transforming Growth Factor-beta, MAPK; Mitogen-Activated Protein Kinase, ACTA2; Alpha Smooth Muscle Actin, COL1A1; Collagen Type I Alpha 1 Chain.*